PYMNTS.com September 5, 2024
As artificial intelligence (AI) promises to remake drug discovery, recent clinical trial results reveal its potential and challenges.
Recursion Pharmaceuticals, a self-described “clinical stage TechBio company,” recently announced results from its Phase 2 SYCAMORE trial for REC-994, a drug candidate targeting cerebral cavernous malformation (CCM), a rare brain disorder. The trial met its primary safety endpoint but showed mixed efficacy results, illustrating the complexities of translating AI-driven discoveries into clinical success.
The company’s Recursion OS platform uses machine-learning algorithms to analyze vast datasets, aiming to identify new drug candidates more efficiently than traditional methods. This approach represents a growing trend in the pharmaceutical industry to leverage AI in drug discovery. It also shows the challenges.
“While artificial intelligence excels at...
Today's Sponsors
Today's Sponsor